Content about Henry Waxman

June 13, 2012
NACDS urges expansion of PDUFA provisions to ensure patient care, curb Rx abuse

As the U.S. Senate and House reconcile their versions of the Prescription Drug User Fee Act, the National Association of Chain Drug Stores on Wednesday urged U.S. House and Senate leaders to expand provisions in the final bill to help ensure that Americans continue to have access to safe and effective prescription medications, while also curbing prescription drug abuse.

ALEXANDRIA, Va. — As the U.S. Senate and House reconcile their versions of the Prescription Drug User Fee Act, the National Association of Chain Drug Stores on Wednesday urged U.S. House and Senate leaders to expand provisions in the final bill to help ensure that Americans continue to have access to safe and effective prescription medications, while also curbing prescription drug abuse.

December 20, 2010
Reform will bolster pharmacy, GAO confirms

A study by the Government Accountability Office confirmed that the health-reform law enacted earlier this year established a more reasonable reimbursement level for pharmacies dispensing generic drugs to patients covered by Medicaid. But pharmacy retailers still face the continued threat of further Medicaid cuts at the state level, the independent pharmacy lobby warned Friday.

ALEXANDRIA, Va. — A study by the Government Accountability Office confirmed that the health-reform law enacted earlier this year established a more reasonable reimbursement level for pharmacies dispensing generic drugs to patients covered by Medicaid. But pharmacy retailers still face the continued threat of further Medicaid cuts at the state level, the independent pharmacy lobby warned Friday.

November 3, 2010
NPA leader weighs in on what elections mean for industry

This year’s elections may prove to be a boon to the business of dietary supplements...

WASHINGTON This year’s elections may prove to be a boon to the business of dietary supplements and other natural alternatives, according to John Gay, Natural Products Association executive director and CEO. “This was the most remarkable election in my 25 years in Washington,” he said, “and the effects will be felt almost immediately.”

For example, Rep. Henry Waxman, D-Calif., who must now step down as chairman of the House Energy and Commerce Committee, is seen as a potential positive for the industry, Gay said.

 

June 11, 2009
Waxman asks Obama to look for alternative pathway for biosimilars

Support for a regulatory pathway for biosimilars has grown rapidly, and even a few branded...

NEW YORK Support for a regulatory pathway for biosimilars has grown rapidly, and even a few branded companies, such as Merck & Co. and Pfizer, have expressed interest. But Rep. Henry Waxman's, D-Calif., request that the Obama administration look for legal means to let the FDA approve biosimilars before his bill, its companion in the Senate or fellow California Democratic Rep. Anna Eshoo’s competing bill is put to a vote, is a strong signal that biogenerics are going to be a reality in American health care — and sooner rather than later.

 

March 12, 2009
Congress takes up follow-on biologics bill

The long-awaited breakthrough for follow-on biologics may be close at hand....

The long-awaited breakthrough for follow-on biologics may be close at hand.

Prompted by a far more supportive President and the growing crisis in healthcare funding, Congress has again taken up the call for a bill that would create a regulatory pathway for FDA approval of generic versions of biologically-engineered drugs. And with the strong affirmation of President Obama, who has campaigned for such an approval pathway, the newest iteration of the bill stands a far better chance of passage than previous attempts in the House and Senate.